As with drug development and biotech tools, the molecular diagnostics market has its major players—companies that include Roche, QIAGEN, Hologic, Grifols, Abbott Laboratories, Siemens Healthcare, Becton Dickinson (BD), Beckman Coulter, and bioMérieux.

DTC genetic tests allow consumers to access information about their genetics without necessarily involving healthcare professionals in the process.

5, Clinical OMICs Magazine Volume 7, Issue No.

But the landscape of genetic health testing has changed dramatically in recent years and 23andMe is no longer alone atop the mountain. 1, Promising COVID-19 Immunotherapy Targets CCR5, Optical Mapping in Rare Genetic Disease Diagnosis, Interpreting NGS Tests for Inherited Disorders, Predicting Breast Cancer Outcomes Using AI Models and Federated Learning, Molecular Diagnostics/In vitro Diagnostics, SARS-CoV-2 Whole Virus and Full Process IVD Controls, DNA Mutational Profiling of Tumor Samples, Myriad’s EndoPredict Receives Positive Coverage Decisions from Anthem, Palmetto, Expanding End-Use Segments Drive PCR Growth Worldwide. Invitae is trusted by doctors around the world. More than a test. As patients take a more proactive role in their own health care, direct-to-consumer (DTC) laboratory testing is becoming increasingly popular.

Most of the companies are listed with results from the first three quarters of 2016 and fourth quarter of 2015, since fourth-quarter and full-year 2016 results were not available at deadline.

Learn how your comment data is processed.

By continuing to use our site, you are agreeing to the use of cookies as set in our, Microneedle Patch Can Extract Interstitial Fluid for Biomarker Testing, First Large-Scale Proteogenomic Analysis of Pediatric Brain Tumors Completed, Tempus Gets CE Mark for its Broad-Panel Genomic Sequencing Test, SARS-CoV-2 Mutations Do Not Increase Transmissibility, Genetics of Miscarriage Risk Uncovered Using Large-Scale Genetic Association Analyses, Specific Immune Cells in Gut Flora Protect Against MS, Clinical OMICs Magazine Volume 7, Issue No. 2, Clinical OMICs Magazine Volume 7, Issue No. Grand View Research in October projected a near-tripling of the market to $17.9 billion in 2024, from $6.45 billion in 2015.

(18) Company disclosed preliminary 2016 revenue figure during 35th Annual J.P. Morgan Healthcare Conference, held January 9-12 in San Francisco.

Affordable pricing.

Our industry-leading labs are equipped with best-in-class technology and staffed by some of the world’s leading genetics experts.

This site uses Akismet to reduce spam.

4, Clinical OMICs Magazine Volume 7, Issue No. (20) Revenue number combines molecular diagnostics testing revenue results reported during the company’s first two fiscal quarters of 2017, and its final two fiscal quarters of 2016. All Rights Reserved. Copyright © 2020 Genetic Engineering & Biotechnology News. Indeed M&A activity has claimed four molecular diagnostics companies listed by sister publication GEN in a 2015 list of up-and-coming companies. (2) 2016 revenue figure includes preliminary fourth-quarter revenue result of approximately $1 million disclosed by the company on January 26, (3) Revenue number combines $3,674,949 reported for the first three quarters of 2016, with $1,215,753 reported for the fourth quarter of 2015, (4) Net sales number combines $1.198 million reported for the first three quarters of 2016, with $4.914 million reported for the fourth quarter of 2015, (5) Revenue number combines $5.336 million reported for the first three quarters of 2016, with $1.501 million reported for the fourth quarter of 2015, (6) Revenue number combines $7.215 million reported for the first three quarters of 2016, with $3.6 million reported for the fourth quarter of 2015, (7) Revenue number combines $245.126 million reported for the first three quarters of 2016, with $74.540 million reported for the fourth quarter of 2015, (8) Revenue number combines €6.109 million reported for the first half of 2016, with €6.757 million reported for the second half of 2015, (9) Revenue number combines $15.812 million reported for the first three quarters of 2016, with $3.161 million reported for the fourth quarter of 2015, (10) Revenue number combines $19.819 million reported for the first three quarters of 2016, with $5.484 million reported for the fourth quarter of 2015, (11) Revenue number combines $22.025 million reported for the first three quarters of 2016, with $5.692 million reported for the fourth quarter of 2015, (12) Revenue number combines $29.771 million reported for the first three quarters of 2016, with $6.648 million reported for the fourth quarter of 2015, (13) Company disclosed projected 2016 revenue figure in a press release on January 10, and a presentation the following day at the 35th Annual J.P. Morgan Healthcare Conference, held January 9-12 in San Francisco, (14) Revenue number combines $46.828 million reported for the first three quarters of 2016, with $14.042 million reported for the fourth quarter of 2015, (15) Revenue number combines $64.135 million reported for the first three quarters of 2016, with $14.420 million reported for the fourth quarter of 2015. You can use DNA testing to highlight health dangers that you may be exposed to in the future. And by being aware of these risks, you can make relevant lifestyle choices today - either for your own health, or the health of any future offspring.

Indeed M&A activity has claimed four molecular diagnostics companies listed by sister publication GEN in a 2015 list of up-and-coming companies. (1) 2016 revenue figure includes preliminary fourth-quarter revenue results disclosed by the company on January 24.

(16) Company disclosed preliminary 2016 revenue figure on January 9 in press release.

And as with the largest companies a few years back, up-and-comers have seen consolidation over the past three years through mergers and acquisitions. The leading company on that list, Cepheid, was acquired last year by Danaher, while Sequenom was absorbed by LabCorp, and Nanosphere by Luminex.

That’s just slightly lower than the $6.54 billion market size estimated for molecular diagnostics last year by MarketsAndMarkets, which foresees the field climbing to $10.12 billion by 2021. A fourth company on the 2015 List, Signal Genetics, is being acquired by Miragen Therapeutics.

Test kits help reveal insights into genetic health risks as well as your chances of being a carrier of a variety of medical conditions. A fourth company on the 2015 List, Signal Genetics, is being acquired by Miragen Therapeutics. Genetic testing has gone mainstream, with services like 23andMe capitalizing on our curiosity and selling genomic insights for a price.

And it’s no wonder, seeing as how information on everything—from how we respond to certain medications, to inherited risk factors—is stored in our DNA .

CTRL + SPACE for auto-complete.

Yet significant activity in molecular diagnostics has come in recent years from smaller companies focused on specific technologies or disease areas, especially cancer. (17) Revenue number combines $167.775 million reported for the first three quarters of 2016, with $52.911 million calculated for the fourth quarter of 2015.

For years, if you wanted to get any health-related information from a DNA test, your only good choice was 23andMe. 23andMe was the first company (in 2017) to receive FDA approval to market genetic risk information for certain conditions. 3, Clinical OMICs Magazine Volume 7, Issue No.

The leading company on that list, Cepheid, was acquired last year by Danaher, while Sequenom was absorbed by LabCorp, and Nanosphere by Luminex. Clinical OMICs – Molecular Diagnostics in Precision Medicine, 20 Molecular Diagnostics Companies to Watch, We use cookies to give you a better experience on clinicalomics.com.

Make Sour Cream, Pinellas County Police Reports, Corning Inc 2019, Extrovert Personality Meaning In Urdu, Great Value Powdered Peanut Butter Nutrition, Homeland Gamecube Iso, Green Tree Logo, Apple Cucumber Smoothie For Weight Loss, Blue Dragon: Awakened Shadow Shadows, Most Expensive Ukulele Brands, 5g Mobile Price In Singapore,